At the 2022 ASCO annual meeting, Matthew Goetz, MD, Mayo Clinic, Rochester, MN, discusses recent research presented at the 2022 ASCO annual meeting related to therapeutic options for breast cancer. Dr Goetz discusses CDK4/6 inhibitors and options for patients following progression on a CDK4/6 inhibitor.
More Videos in Metastatic Breast Cancer Content Hub
Aditya Bardia, MD, MPH, director of translational research integration, UCLA, explains how metastatic estrogen receptor-positive breast cancers can develop ESR1 mutations. Donald McDonnell, PhD, research scientist, Duke University,…
Javier Cortés, MD, PhD, head of the International Breast Cancer Centre (IBCC), Barcelona, Spain, reviews subgroup analyses from the Phase 3 EMERALD trial. Professor Cortés discusses how these…
In this video, Frédérique Penault-Llorca, MD, PhD, professor of pathology, University of Clermont-Ferrandand, France, and Aditya Bardia, MD, MPH, director of translational research integration, UCLA, discuss the current…
With a wave of FDA approvals and promising clinical trials, treatment options for metastatic breast cancer are expanding fast. Amy Tiersten, MD, highlights the power of immunotherapies—especially checkpoint…
Angela Belcher, PhD; Sangeeta Bhatia, MD, PhD; and Paula Hammond, PhD, from the Koch Institute at MIT, Cambridge, MA, present multi-dimensional approaches to early detection in ovarian cancer.…
Approximately 30% of women with early-stage breast cancer will face metastatic disease, and 6% are diagnosed with metastatic breast cancer initially. Living with metastatic breast cancer can elicit…
In this video, Sarah DiGeronimo, NP, and Sydney Smith, PharmD, both from Dana-Farber Cancer Institute, Boston, Massachusetts, discuss tips for the management of common side effects resulting from…
Part 1 – Case Presentation Gabriel N. Mannis, MD, presents the case of patient “J.A.” to fellow faculty members Brian A. Jonas, MD, PhD, FACP, and Daniel A.…